The 24th Annual Conference of the Women’s Cancer Initiative–Tata Memorial Hospital (WCI–TMH) is emphasizing the integration of molecular diagnostics, precision radiotherapy, targeted therapies, and immunotherapy to expand treatment options for women with advanced gynaecological cancers. The event began on October 8, 2026, with pre-conference workshops held on the 8th and 9th, followed by the two-day main scientific conference commencing on October 10.
The conference themed ‘Gynaecological Cancers: Evidence meets Practice’, is taking place at the R D Choksi Auditorium, Tata Memorial Hospital, Mumbai. The meeting has brought together Indian and invited international cancer specialists to examine evolving treatment strategies, multidisciplinary care, and the application of emerging scientific evidence to clinical decision-making.
Gynaecological cancers continue to pose a significant health burden in India. According to GLOBOCAN 2024 estimates, more than 1.5 lakh new cases of cervical, ovarian, and uterine corpus cancers were estimated in the country in 2024.
One of the major developments in gynaecological oncology has been the shift beyond conventional staging and histological grading towards a more precise understanding of tumour biology. Hereditary cancer gene panels and molecular diagnostics are increasingly informing risk assessment, identifying inherited cancer susceptibility, and guiding treatment selection. Genetic testing in ovarian cancer and molecular classification in endometrial cancer are helping clinicians identify patients who may benefit from specific treatment approaches.
Advances in surgical techniques, precision radiotherapy, targeted therapies, and immunotherapy have expanded treatment options for women with advanced gynaecological cancers. Recent clinical evidence has demonstrated improvements in survival in selected patient populations, including women with locally advanced cervical cancer and advanced or recurrent endometrial cancer.
The international faculty participating in the Conference includes Dr Yves Delporte, Honorary Professor of Oncology at the University of Toulouse, France, and former President of the European Society of Gynaecological Oncology, and Dr Jacques Delorme of Pitié-Salpêtrière University Hospital, Sorbonne University, Paris, France.
Source:
Press Information Bureau
